摘要
目的:观察参苓白术散加减治疗脾虚型亚急性湿疹患者的临床疗效,研究其对炎症因子和外周血T淋巴细胞亚群的影响,为临床治疗提供理论依据。方法:选取本院2016年1月至2017年12月诊治的176例脾虚湿蕴型湿疹患者作为研究对象,随机分为对照组(88例)和观察组(88例),对照组给予盐酸左西替利嗪片和复方硝酸益康唑凝胶治疗,观察组在对照组的基础上给予参苓白术散加减,治疗4周。观察两组患者临床疗效、治疗前后瘙痒评分、严重度指数(severity index,EASI)评分、皮肤病生活质量表(dermatology quality of life scales,DQOLS)评分、炎症因子及外周血T淋巴细胞亚群水平变化情况;随访6个月观察患者的复发情况。结果:治疗后,观察组患者瘙痒评分和EASI评分较本组治疗前降低,且观察组明显低于对照组(P <0. 05); DQOLS评分较本组治疗前升高,且观察组明显高于对照组(P <0. 05)。观察组患者临床有效率明显高于对照组(P <0. 05)。治疗后,观察组患者白细胞介素(interleukins,IL)-1β,IL-2,IL-4,IL-5,肿瘤坏死因子(tumor necrosis factor,TNF)-α水平较本组治疗前降低,且观察组明显低于对照组(P <0. 05);两组CD4+,CD4+/CD8+水平较本组治疗前升高,且观察组明显高于对照组(P <0. 05)。随访6个月,观察组患者复发率明显低于对照组(P <0. 05)。结论:参苓白术散加减通过抑制患者炎症反应,增强免疫功能,从而提高临床疗效。
Objective: To observe the clinical efficacy modified Shenling Baizhu San in treating patients with spleen deficiency wetness type subacute eczema,and its effect on the inflammatory factors and peripheral blood T lymphocyte subsets,so as to provide a theoretical basis for clinical treatment. Method: Totally 176 cases of spleen deficiency wetness type subacute eczema treated at our hospital from Jan. 2016 to Dec. 2017 were selected and randomly divided into control group(88 cases) and observation group(88 cases). Control group was treated with levocetirizine hydrochloride tablets and compound econazole nitrate gel,and observation group was given modified Shenling Baizhu San in addition to therapy of control group for 4 weeks. The clinical efficacy,pruritus score,severity index(EASI) score,dermatology quality of life scales(DQOLS) score and recurrence rate were observed,and inflammatory factor and peripheral blood T lymphocyte subgroup level were detected. Result: After treatment,the pruritus score and EASI score in observation group were lower than those before treatment(P < 0. 05),and those of observation group were significantly lower than those of control group(P < 0. 05).However,the DQOLS score was higher than that before treatment,and significantly higher than that of control group(P < 0. 05). The clinical effective rate of observation group was significantly higher than that of control group(P < 0. 05). After treatment,the levels of interleukins(IL)-1β,IL-2,IL-4,IL-5 and tumor necrosis factor(TNF)-α in observation group were lower than those before treatment(P < 0. 05),and the levels of CD4+and CD4+/CD8+were higher than those of before treatment,and significantly higher than those of control group(P <0. 05). During the 6-month follow-up,the recurrence rate of observation group was significantly lower than that of control group(P < 0. 05). Conclusion: Modified Shenling Baizhu San could enhance the clinical efficacy by inhibiting the inflammatory reaction and regulating the immune function of patients.
作者
蔚志仁
石晶
王彩霞
郭鑫
谷永革
张宇
YU Zhi-ren;SHI Jing;WANG Cai-xia;GUO Xin;GU Yong-ge;ZHANG Yu(Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital,Tianjin 300120,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2019年第5期63-67,共5页
Chinese Journal of Experimental Traditional Medical Formulae
基金
天津市中医药管理局中医中西医结合科研项目(13018)
关键词
参苓白术散
湿疹
脾虚湿蕴型
炎症因子
T淋巴细胞亚群
Shenling Baizhu San
eczema
spleen deficiency wetness type
inflammatory factors
T lymphocyte subsets
